BBC - BioShares Biotechnology Clinical Trials ETF
|Ex-Dividend Date||Dec 20, 2017|
|Trading Day||April 21|
|Day's Range||48.13 - 49.16|
|52-Week Range||33.02 - 62.60|
The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering (lead drug) that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
|Asset Class |
|Inception Date |
Dec 16, 2014
|Ticker Symbol |
|Index Tracked |
BioShares Biotechnology Clinical Trials Index
Top 10 Holdings14.56% of assets
|Five Prime Therapeutics Inc||FPRX||1.38%|
|Bny Mellon Cash Reserve Usd||CBI.MI||1.34%|
|Applied Molecular Transport||AMTI||1.18%|
These funds could be the best ways for investors to tap the opportunity arising from the Bristol Myers-MyoKardia deal and will likely see smooth trading in the months to come.
Small-cap biotech ETFs may prove to be winning bets with or without coronavirus.
Biotechnology ETFs, including the ALPS Medical Breakthroughs ETF (SBIO), are on torrid paces in the second quarter. Yes, some of that bullishness is attributable to the industry’s efforts to vanquish th...
This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?
Failure to Launch: The ETF Built to Fight the Coronavirus That Never Came to Be
Bloomberg's Eric Balchunas and Scarlet Fu break down the Virtus LifeSci Biotech Clinical Trials ETF (ticker: BBC) with Paul Yook, CIO of LifeSci Venture Partners.
Despite concerns of a spreading coronavirus out of China, biotechnology stocks and sector-related ETFs are not enjoying the usual bump on hopes of developing new treatments to counter the contagion. Amo...
As there have been winners in many corners of the space, we highlight nine ETFs from different zones that have outperformed so far this year. These are expected to continue outperforming, provided the f...
ETF Trends CEO Tom Lydon discussed the Virtus LifeSci Biotech Clinical Trials ETF (BBC) on this week’s “ETF of the Week” podcast with Chuck Jaffe on the MoneyLife Show. BBC seeks investment results that...
Head: Why Biotech ETFs are Rising
Increasing M&A deals and cutting edge therapies are driving biotech ETFs higher.
Investors have been piling into exchange traded funds again this year, mostly pure beta, core equity and fixed income funds.
The S&P 500 hit record highs last week, with the index rising for the fourth consecutive week, marking its longest winning streak since March.